PYC THERAPEUTICS LIMITED

8.24%

92.0¢

Market Cap $516.1M

Healthcare Biotechnology

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Latest Threads

Tag

Subject

PYC Betting

The Chairman has to go …

12:34

1.8K

12:34

Last post ralom

1.8K

PYC

PYC - General Discussion

16 17 18

11:49

1.0K

550K

11:49

Last post travelbug2

1.0K

550K

PYC

Ann: Change of Managing Director

17/09/25

17K

17/09/25

Last post Lifeisabeach

17K

PYC

Ann: ADOA Program - Presentation of Clinical Data at NOSA 2025

05/09/25

2.6K

05/09/25

Last post hottod

2.6K

PYC

Ann: PKD Program - Presentation of Safety Data at ANZSN

01/09/25

2.5K

01/09/25

Last post travelbug2

2.5K

PYC

Ann: 2025 Annual Report to Shareholders

29/08/25

1.9K

29/08/25

Last post standalone

1.9K

PYC

Ann: 2025 Corporate Governance Statement

28/08/25

207

28/08/25

Last post

ASX News

207

PYC

Ann: Appendix 4G

28/08/25

149

28/08/25

Last post

ASX News

149

See All Discussions

Timeline

Change of Managing Director
17 Sep 08:27	Share

ADOA Program - Presentation of Clinical Data at NOSA 2025
05 Sep 09:03	Share

PKD Program - Presentation of Safety Data at ANZSN
29 Aug 08:37	Share

2025 Corporate Governance Statement
28 Aug 17:24	Share

Appendix 4G
28 Aug 17:22	Share

2025 Annual Report to Shareholders
28 Aug 17:18	Share

Appendix 4E
28 Aug 17:15	Share

Approval to Escalate Dosing in Kidney Disease Clinical Trial
08 Aug 08:59	Share

Q3 2025 Investor Webinar Presentation
01 Aug 08:34	Share

Q3 Investor Webinar 1 August 2025
28 Jul 08:59	Share

Quarterly Activities/Appendix 4C Cash Flow Report
21 Jul 08:42	Share

Approval to Progress Kidney Disease Trial to Next Stage
07 Jul 08:57	Share

Fourth Drug Program Progressing to Human Trials
27 Jun 09:11	Share

FDA Alignment on Registrational Trial Design RP11 Program
23 Jun 08:57	Share

SRC Approves Dose Escalation in ADOA Clinical Trial
11 Jun 09:17	Share

Investor Webinar Presentation
30 May 08:59	Share

Approval to Escalate Dosing in Kidney Disease Trial
26 May 09:13	Share

Notification of cessation of securities - PYC
23 May 16:29	Share

Q2 Investor Webinar 30 May 2025
13 May 09:32	Share

Foundation Fighting Blindness Presentation Materials
02 May 08:31	Share

Change in substantial holding
28 Apr 16:33	Share

Presentation of Clinical Proof of Concept in Lead Program
28 Apr 09:02	Share

Quarterly Activities/Appendix 4C Cash Flow Report
24 Apr 08:48	Share

Application for quotation of securities - PYC
23 Apr 17:44	Share

Completion of Entitlement Offer
17 Apr 08:35	Share

First Subject Dosed in PKD Clinical Trial
10 Apr 08:45	Share

Placement of Shortfall
09 Apr 09:45	Share

Investor Webinar Presentation
28 Mar 09:17	Share

Application for quotation of securities - PYC
21 Mar 09:40	Share

Q1 Investor Webinar 28 March 2025
21 Mar 09:38	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 92.0¢		Change 0.070(8.24%)		Mkt cap ! $516.1M

Open	High	Low	Value	Volume
89.0¢	93.0¢	86.5¢	$1.850M	2.079M

Buyers (Bids)

No.	Vol.	Price($)
4	6377	91.0¢

Sellers (Offers)

Price($)	Vol.	No.
92.0¢	4085	8

View Market Depth

No.	Vol.	Price($)
6	12580	0.920
4	53711	0.915
4	16576	0.910
2	2634	0.905
2	732	0.900

Price($)	Vol.	No.
0.925	4025	4
0.930	33571	2
0.935	49679	2
0.940	20652	2
0.945	16159	3

Last trade - 12.15pm 18/09/2025 (20 minute delay)


Last 91.0¢		Change 0.070 ( 5.76 %)
Open	High	Low	Volume
89.5¢	92.0¢	86.5¢	139491
Last updated 12.32pm 18/09/2025 ?

PYC (ASX) Chart

PYC THERAPEUTICS LIMITED

Latest Threads

Green light for NUZ-001: Neurizon secures significant R&D incentive

Timeline

Featured News

Latest Videos

PYC Therapeutics (ASX:PYC) lands FDA clearance for first human trials of RP11 treatment drug

06 Mar 2023 13:04 (AEDT)

Latest Articles

PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit

PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.(Most gains, however, were quickly sold off.)Autosomal Dominant Optic Atrophy (ADOA)...

Scientific conference spotlights PYC's work on blindness disease treatment

PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore

PYC Therapeutics moves into final stage of child blindness study

PYC has been approved to escalate doses of its drug candidate VP-001, treating Retinitis Pigmentosa 11, in a second patient cohort.

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News